CDK4/6 Inhibitor Efficacy in <i>ESR1</i> -Mutant Metastatic Breast Cancer-Reference-Cited by-同舟云学术

CDK4/6 Inhibitor Efficacy in ESR1 -Mutant Metastatic Breast Cancer

Published:2024-04-23 Issue:5 Volume:3 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Lloyd Maxwell R.¹,Brett Jamie O.²³,Carmeli Ariel⁴⁵,Weipert Caroline M.⁶,Zhang Nicole⁶,Yu Junhua⁶,Bucheit Leslie⁶,Medford Arielle J.²,Wagle Nikhil³⁷,Bardia Aditya²,Wander Seth A.²

Affiliation:

1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston

2. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston

3. Dana-Farber Cancer Institute, Harvard Medical School, Boston

4. The Broad Institute of MIT and Harvard, Cambridge, MA

5. Count Me In: Patient-Partnered Research, Cambridge, MA

6. Guardant Health, Palo Alto, CA

7. Genentech, South San Francisco, CA

Publisher

Massachusetts Medical Society

Reference29 articles.

1. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

2. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role

3. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

4. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

5. A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leveraging Molecular Information for Optimal Treatment Recommendations;NEJM Evidence;2024-04-23